ENLIVEX LTD

ENLV stock represents shares of Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company. The ticker trades on the Nasdaq Capital Market under the symbol ENLV. As a clinical-stage biotech, its value is tied to the progress of its drug development programs and related regulatory milestones rather than commercial product sales.

ENLV operates in the biotechnology and pharmaceuticals industry, specifically in the development of immunotherapies. The company focuses on innovative cell-based and drug candidates aimed at treating inflammatory and autoimmune conditions. Its business sits within the broader healthcare sector, where research and clinical trial outcomes heavily influence investor sentiment toward the stock.

Recent performance for ENLV depends on changing market conditions and company-specific developments. The latest price, percentage moves, and trading volume are shown in the quote data on this page. Reviewing that up-to-date information alongside recent news gives a clearer picture of how the stock has been trading.

The 52-week range shows the lowest and highest prices ENLV has traded at over the past year. This measure helps investors gauge recent volatility and where the current price sits within that band. The latest 52-week high and low for ENLV are available in the key statistics section on this page.

Valuing ENLV is not straightforward because clinical-stage biotechs often have limited or no revenue. Traditional metrics like the P/E ratio may be less meaningful, so investors frequently look at cash position, research pipeline progress, and potential market opportunities for its drug candidates. The valuation metrics displayed on this page provide the latest available figures for analysis.

ENLV carries significant risks typical of clinical-stage biotechnology companies. Clinical trials may fail or be delayed, regulatory approvals may not be granted, and the company may need to raise additional capital, which can dilute shareholders. Its stock price can be highly volatile and sensitive to news about drug development, competitive landscape, and overall market conditions.